Medical device developer LightIntegra Technology said last Friday it raised $3.5 million in financing from its existing shareholder base to support its blood diagnostic tech development.
The Vancouver-based company is developing diagnostics looking to reduce blood transfusions in cancer patients and minimize platelet refractoriness.
LightIntegra’s flagship device is the ThromboLUX, which identifies non-activated platelet products which are optimal for the patient types. The system was commercially launched in the US in April, this year.
“This funding will help LightIntegra advance its commercialization efforts in the USA, and serves as a positive indication of the company’s shareholder support. The financing allows our company to generate working capital while maintaining its existing ownership structure,” CEO Bill Dubiel said in a prepared statement.